Two-Year Results Published From the ISAR-ABSORB Registry of Everolimus-Eluting Bioresorbable Stents in Routine Practice
June 26, 2017—Two-year clinical outcomes from the ISAR-ABSORB registry of patients treated in routine practice with everolimus-eluting bioresorbable stent (BRS) implantation were reported by Jens Wiebe, MD, et al in Journal of the American College of Cardiology (JACC): Cardiovascular Interventions.
As summarized in JACC: Cardiovascular Interventions, the ISAR-ABSORB registry enrolled consecutive patients undergoing BRS implantation in routine clinical practice at two high-volume centers in Munich, Germany. Angiographic follow-up was scheduled after 6 to 8 months and clinical follow-up to 24 months. The primary endpoint was the composite of death, myocardial infarction, or target lesion revascularization. Secondary endpoints included individual components of the primary endpoint and definite stent thrombosis. Event rates were calculated using the Kaplan-Meier method.
The study was composed of 419 patients (mean age, 66.6 ± 10.9 years; 31.5% had diabetes; 39% presented with acute coronary syndrome). Additionally, 49% of lesions were considered complex and 13.1% were bifurcation lesions. The mean reference vessel diameter was 2.89 ± 0.46 mm. At 2 years, the primary endpoint had occurred in 21.6% of patients (death, 6.3%; myocardial infarction, 3.9%; target lesion revascularization, 16%; definite stent thrombosis, 3.8%).
The investigators concluded that the long-term follow-up of patients treated with BRS in routine practice showed higher event rates than expected. Future studies are required to determine the effect of changes in implantation technique and to define the optimal duration of dual antiplatelet therapy in these patients, advised the investigators in JACC: Cardiovascular Interventions.
In April 2016, the ISAR-ABSORB investigators published 1-year findings from an evaluation of the angiographic and clinical outcomes of these patients in Catheterization and Cardiovascular Interventions. The investigators reported that the use of everolimus-eluting BRS in routine clinical practice was shown to be associated with high antirestenotic efficacy in patients undergoing angiographic surveillance. Overall clinical outcomes at 12 months were satisfactory, but stent thrombosis rates were not insignificant.